PLYGF (PolyPeptide Group AG) Current Accrued Expense: $0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLYGF PolyPeptide Group AG PLYGF
59 GF Score
Price $54.42
GF Value $41.41
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Current Accrued Expense?

PolyPeptide Group AG PLYGF +26.56% 59 Current Accrued Expense is $0.0 Mil as of Dec. 2025. GuruFocus rates PLYGF with a GF Score™ of 59/100 and a GF Value™ of $41.41 (Significantly Overvalued). The stock has 6 warning signs investors should review.

PolyPeptide Group AG's Current Accrued Expense for the quarter that ended in Dec. 2025 was $0.0 Mil.

PolyPeptide Group AG Current Accrued Expense Related Terms

PolyPeptide Group AG Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Current Accrued Expense Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PLYGF
59GF Score
PolyPeptide Group AG PLYGF
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.0 Mil mean?
PolyPeptide Group AG (PLYGF) has a Current Accrued Expense of $0.0 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Current Accrued Expense too high?
PolyPeptide Group AG's current Current Accrued Expense is $0.0 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Current Accrued Expense compare to ZTS and UTHR?
PolyPeptide Group AG's Current Accrued Expense of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Current Accrued Expense is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $41.41, compared to a current price of $54.42 — trading 31.4% above its estimated fair value. The current Current Accrued Expense is $0.0 Mil. PolyPeptide Group AG's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current Current Accrued Expense is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of $54.42 is trading 31.4% above its estimated GF Value™ of $41.41. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for PLYGF:

  • Current Accrued Expense: $0.0 Mil
  • GF Value™: $41.41 vs. price of $54.42 (31.4% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
59GF Score

Get the complete analysis for PLYGF

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.42
Price
$41.41
GF Value